The American Veterinary Medical Association has convened a MUMS roundtable to advance drug availability for minor uses and minor species in animal medicine. The meeting addresses a persistent gap: many animals treated in practice lack approved pharmaceutical options.

The roundtable's name refers to the Minor Use and Minor Species Animal Health Act, the legislative framework intended to stimulate drug development where the commercial market is small. Drugs for sheep, goats, game birds, zoo animals, aquaculture species, and uncommon indications in major species often lack full approvals.

What is at stake for practitioners?

Clinicians treating minor species frequently work without labeled products. That reality pushes veterinarians toward extralabel use, compounding, and best-guess dosing. The roundtable examined how to change that picture at the level of the exam table and in the barn.

The discussion covered approaches to expanding the number of approved drugs available under the MUMS framework. Participants looked at the mechanisms that exist to reward sponsors for pursuing limited-market approvals.

Which tools does MUMS provide?

The framework offers designated new animal drugs, conditional approvals, and indexing for species too few in number for effective food-safety testing. These pathways, overseen by the FDA Center for Veterinary Medicine, exist to shorten the route from research to approved label for minor uses.

Roundtable participants reviewed how these tools perform in practice and where they fall short. The goal stated in the meeting's framing is greater drug availability — more approved options, not merely more legal workarounds.

How does this affect different practice types?

For companion-animal practice, the stakes show up in uncommon diseases in dogs and cats, where a minor use in a major species may have no approved therapy. For food-animal practice, sheep, goats, and farmed aquaculture species face the widest gaps, with direct consequences for residue avoidance and responsible treatment.

Public health is also part of the equation. Approved labels carry established withdrawal intervals and dosing guidance, which extralabel use and compounding cannot always match. Broader availability of approved products supports judicious antimicrobial use and safer food production.

What comes next?

The roundtable represents a continuing effort rather than a single decision point. Stakeholders signaled intent to keep pushing on incentives, sponsor engagement, and regulatory pathways that convert limited-market demand into approved animal drugs. Practitioners can expect the MUMS agenda to remain active as participants work toward concrete additions to the approved drug arsenal.